SJLife Sciences noted that MIRA Pharmaceuticals reported positive tox data for MIRA-55, supporting IND enabling studies in inflammatory pain.
Public source
Publisher name
Public post
🚨 🧠 Neuroscience News – 2 week recap: 04/09 – in partnership with World CNS Series 🥼 Clinical News Ionis Pharmaceuticals, Inc. secured FDA approval for Zanvastro for…
Company
SJLife Sciences
part of The SJGroup
- Industry
- Staffing and Recruiting
- Location
- Greater Boston, US
- Company size
- 2–10 employees
About SJLife Sciences
SJLife Sciences are a Global Talent Partner that exclusively serves the Pharmaceutical, Biotechnology, Medical Device, and CRO sectors. Our Mission is to provide a focused, quality-driven consultative offering that combines an exceptional market understanding of the Life Science industry with a dedication and passion to go above and beyond for our clients and candidates. We want to do more than just recruit the right people for the right role. We want to build partnerships that change people's lives. We recognize the expanding and growing need for talent within the life sciences industry, which is why we have consultants dedicated to placing candidates with the right skills and experience across our European and US markets. Combined with our expertise and deep knowledge of the life sciences industry, we can become your lifelong partner in an exciting career. Whether you’re potentially looking for a new opportunity or looking to attract talent to your team, we’d love to hear from you.
See moreLatest activity
Latest activity from SJLife Sciences
11 signals
Capital & Finance
SJLife Sciences reported that the Phase 3 Harbor trial of del-desiran for Novartis' $12B Avidity acquisition of Avidity Biosciences, Inc. missed its primary endpoint in myotonic dystrophy type 1.
Legal & Regulatory
SJLife Sciences noted that Ultragenyx missed its primary and key secondary endpoints in the Ph 3 Aspire study of apazunersen in Angelman syndrome.
Legal & Regulatory
SJLife Sciences noted that Takeda secured approval in Japan for ORZEYFUL, targeting narcolepsy type 1.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Slone Partners
Slone Partners reported that Ionis Pharmaceuticals, Inc. received FDA approval for the Ionis ASO Zanvastro for Alexander activity.
Legal & Regulatory
Consult
Consult noted that FibroBiologics (Nasdaq: FBLG) has announced a new US patent covering the use of fibroblasts and fibroblast-derived materials in wound healing.
Legal & Regulatory
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. announced positive results from its completed 7-day dose-range-finding toxicology studies in rats and dogs supporting the next phase of its ongoing IND-enabling program.
Legal & Regulatory
The FDA Group
The FDA Group reported that the FDA sent a clear warning to companies relying on foreign clinical trial data, stating that good data may not be enough if the FDA cannot verify it and can't confirm that a study was conducted according to GCP.
Research & Knowledge
Marcus & Associates - Life Sciences & Healthcare Recruitment Experts